Abliva logo

Abliva Investor Relations Material

Abliva AB, engages in the research and development of mitochondrial medicine for the treatment of neurodegenerative diseases in Sweden. The company's lead candidate is NGM282, an engineered hormone that drives expression of the human glucokinase gene, which is in Phase 2b/3a clinical study as a once-weekly treatment for type 2 diabetes and has completed Phase 1b/2a clinical study to treat non-alcoholic steatohepatitis; and completed a Phase 2 clinical study in patients with primary biliary cholangitis disease

Upcoming events for

Q3 20222022-11-22

Latest company events

Ticker symbol




Investor Relations Page


Dig deeper into the Abliva fundamentals on Quartr.

  • Skip straight to the Q&A session
  • Receive notifications about new events
  • Connect the financial calender on your phone
  • Figure out why the stock is up or down
  • Read the transcripts or scroll the deck
  • Access earnings or press releases
App store link
Android play link
Quartr app screenshot